China's Akeso Soars After New Cancer Drug Beats Market Leader in Clinical Trials

Akeso's stock surged after announcing promising lung cancer treatment results, outperforming Merck's Keytruda in a phase III trial. Ivonescimab showed increased progression-free survival and is pending approval in China, with potential for significant commercial success.